Evidence map›Paper›PMID 32405058›Full record

ReviewNature medicine2020

Caring for patients with cancer in the COVID-19 era.

Joris van de Haar, Louisa R Hoes, Charlotte E Coles, Kenneth Seamon, Stefan Fröhling, Dirk Jäger, Franco Valenza, Filippo de Braud, Luigi De Petris, Jonas Bergh and 11 more

Erratum issued Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04738708 (Telegenetics or In-Person Genetic Counselling), which is not on this map. Cited by 206 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
206citing papers in PubMed, 10 pooled it
26.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04738708 recruitingnot on this mapstarted 2021, after this paper: background citation

Telegenetics or In-Person Genetic Counselling: A Comparison of Clinical Outcomes and Cost

TypeobservationalSponsorNational Cancer Centre, SingaporeRan2021 to 2026Enrolled150ConditionsGenetic CounsellingArmsPatients referred to CGS at NCCS for HBOC or Lynch syndrome pre-test genetic counselling.
3 · Its place in the literature

Who cites it

206 citing papers in PubMed, 10 syntheses or guidelines pooled it, 342 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.Annals of oncology : official journal of the European Society for Medical Oncology · 2020
    Guideline
  7. Pooled it
  8. The COVID-19 pandemic: considerations for resuming normal colorectal services.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2020
    Guideline
  9. Guideline
  10. The Effects of COVID-19 on Cancer Care Provision: A Systematic Review.Cancer control : journal of the Moffitt Cancer Center
    Pooled it
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. The impact of COVID-19 pandemic on cancer patients' health and healthcare: findings from a cross-sectional survey on more than 3000 patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  18. Article
  19. Review
  20. Article

146 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 7 countries.

Joris van de Haar *Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Louisa R Hoes *Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Charlotte E ColesCancer Research UK Cambridge Cancer Center, Cambridge, UK.
Kenneth SeamonCancer Research UK Cambridge Cancer Center, Cambridge, UK.
Stefan FröhlingGerman Cancer Consortium, Heidelberg, Germany.
Dirk JägerDepartment of Medical Oncology, National Center for Tumor Diseases Heidelberg and Heidelberg University Hospital, Heidelberg, Germany.
Franco ValenzaUniversità Statale di Milano, Milan, Italy.
Filippo de BraudUniversità Statale di Milano, Milan, Italy.
Luigi De PetrisDepartment of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Jonas BerghDepartment of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Ingemar ErnbergDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.
Benjamin BesseGustave Roussy Cancer Campus, Villejuif, France.
Fabrice BarlesiGustave Roussy Cancer Campus, Villejuif, France.
Elena GarraldaDepartment of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Alejandro Piris-GiménezDepartment of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Michael BaumannGerman Cancer Consortium, Heidelberg, Germany.
Giovanni ApoloneFondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Jean Charles SoriaGustave Roussy Cancer Campus, Villejuif, France.
Josep TaberneroDepartment of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.ORCID http://orcid.org/0000-0002-2495-8139
Carlos CaldasCancer Research UK Cambridge Cancer Center, Cambridge, UK. carlos.caldas@cruk.cam.ac.uk.ORCID http://orcid.org/0000-0003-3547-1489
Emile E VoestDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. e.voest@nki.nl.ORCID http://orcid.org/0000-0001-8249-9586
The Netherlands Cancer Institute · NLVall d'Hebron Hospital Universitari · ESCancer Research UK Cambridge Center · GBGerman Cancer Research Center · DEInstitut Gustave Roussy · FRKarolinska University Hospital · SEUniversity of Milan · ITCancer Research UK · GBCentre National de la Recherche Scientifique · FRFondazione IRCCS Istituto Nazionale dei Tumori · ITHeidelberg University · DEKarolinska Institutet · SE

Funding

Cancer Research UK 29567Department of Health NIHR300024
6 · The paper itself

Abstract

The current COVID-19 pandemic challenges oncologists to profoundly re-organize oncological care in order to dramatically reduce hospital visits and admissions and therapy-induced immune-related complications without compromising cancer outcomes. Since COVID-19 is a novel disease, guidance by scientific evidence is often unavailable, and impactful decisions are inevitably made on the basis of expert opinions. Here we report how the seven comprehensive cancer centers of Cancer Core Europe have organized their healthcare systems at an unprecedented scale and pace to make their operations 'pandemic proof'. We identify and discuss many commonalities, but also important local differences, and pinpoint critical research priorities to enable evidence-based remodeling of cancer care during the COVID-19 pandemic. Also, we discuss how the current situation offers a unique window of opportunity for assessing the effects of de-escalating anticancer regimens, which may fast-forward the development of more-refined and less-toxic treatments. By sharing our joint experiences, we offer a roadmap for proceeding and aim to mobilize the global research community to generate the data that are critically needed to offer the best possible care to patients.

Indexed as

BetacoronavirusNeoplasmsAmbulatory CareCoronavirus InfectionsCOVID-19Delivery of Health CareHumansPandemicsPneumonia, ViralSARS-CoV-2

Identifiers

PMID32405058
OpenAlexW3016774956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.